FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models

 
• By Sue Sutter
Gottlieb at Bookings July 2018
FDA Commissioner Scott Gottlieb had some choice words for innovators at the unveiling of the Biosimilar Action Plan at the Brookings Institution.

More from Strategy

More from Business